# Pizarra — PT-pseudo_20ba3f0f6ca0 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_20ba3f0f6ca0
Task: 1

Encounter: Urology - outpatient on 01 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 65-year-old male
  - PSA: 4.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.086 ng/mL²
  - PSA velocity: 0.35 ng/mL/yr
  - Prior PSA: 3.8 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 3
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7257912 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 4.8 ng/mL. PI-RADS 4. PSAD 0.09. Prostate volume 56 mL. DRE nodus. csPCa 0.73.

Vitals: weight 76 kg, height 188 cm, BMI 21.5, BP 131/58 mmHg, HR 71 bpm. Smoking: Ex-smoker (11 pack-yr, quit 2023).

Chief complaint: A recent elevation of prostate-specific antigen to 4.8 ng/mL, coupled with a multiparametric MRI conducted at Jeroen Bosch Ziekenhuis, prompted this consultation.

History: A semi-retired musician with a smoking history of 11 pack-years (cessation in 2023) seeks evaluation for a progressively rising PSA and recent imaging results. He reports zero lower urinary tract symptoms, denies haematuria, bone pain, or unexplained weight loss, and maintains a daily 45-minute walking routine alongside a modest alcohol intake of roughly 2 units weekly. Following a recent move, he now shares a residence with his sister, who acts as his next of kin, while his marital status remains married though he currently lives apart from his spouse. Past medical encounters include a routine audiology assessment for mild hearing loss and a dermatology visit for actinic keratosis surveillance; otherwise, his health history is clear, with no comorbidities and no active medications. His prior biopsy bucket remains None. He relies on written summaries during consultations due to mild hearing impairment.

Physical examination: DRE — texture: firm, mobility: unrestricted, asymmetry: Nodus palpable in the right mid-gland peripheral zone. Abdominal and cardiovascular assessments show no abnormalities, recording a blood pressure of 131/58 mmHg and a regular heart rate of 71 bpm. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: musician (semi-retired); Married; Recently relocated; lives with sister.
Next of kin: Sibling (sister).

Lifestyle: alcohol 2 units / week; exercise Walking 45 min/day; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Audiology — hearing test; Dermatology — actinic keratosis check.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.70 +/- 0.12   (95% CI 0.48-0.93)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.12  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.88 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant biopsy?
  - previous_notes (get_previous_notes) -> What is the prior management context and agreed-upon surveillance pathway?

This case hinges on the interpretation of the mpMRI findings and the trajectory of the PSA, as the statistical prior and protocol guideline are based only on the visible panel.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, missing the context of the mpMRI prose, the PSA trajectory (velocity), and the specific DRE finding (Nodus). It did not account for the patient's age (65), PSA density (0.086 ng/mL²), or the specific PI-RADS score (4) in relation to the guideline's risk matrix.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.70), but the guideline criterion is based on PI-RADS $\ge 3$. The prior did not weigh the specific PI-RADS 4 score against the PSA density (0.086 ng/mL²) or the low PSA velocity (0.35 ng/mL/yr), which might suggest a lower risk profile than the model assumed. The high aleatoric uncertainty (H=0.88) suggests the model struggles with the data distribution, potentially misclassifying this specific combination of features.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
1. radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion? (To confirm the guideline trigger).
2. psa_trend - Is the PSA trend significant enough to warrant biopsy? (To assess the velocity context).
3. previous_notes - What is the prior management context and agreed-upon surveillance pathway? (To see if prior management influenced the current decision).
4. laboratory panel - What is the full laboratory panel? (To fully assess PSA density context against guideline thresholds).

GUIDELINE ANCHOR
The guideline states that biopsy is indicated when the mpMRI shows a PI-RADS 3 or higher lesion.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_20ba3f0f6ca0", "radiology_report": "Study: Multiparametric MRI Prostate | Facility: Jeroen Bosch Ziekenhuis ('s-Hertogenbosch) | Date: 28 Dec 2024\nClinical Indication: Evaluation of a 65-year-old male with a PSA value of 4.8 ng/mL and a prior PI-RADS 4 on screening.\nFINDINGS: The prostate gland measures 56.0 mL in volume. T2-weighted sequences reveal a focal area of marked hypointensity within the right peripheral zone at the mid-gland level, spanning approximately 12 x 9 x 8 mm. Restricted diffusion is noted on DWI with corresponding low signal on the ADC map. Dynamic contrast-enhanced sequences demonstrate early, focal enhancement relative to the surrounding parenchyma. The seminal vesicles appear unremarkable. No extracapsular extension or suspicious lymphadenopathy is identified.\nIMPRESSION: PI-RADS 4 lesion in the right peripheral zone mid-gland, consistent with a high probability of clinically significant prostate cancer. Prostate volume 56.0 yields a PSA density of 0.086 ng/mL/mL. csPCa predicted probability 0.7257912."}
get_psa_trend
{"case_id": "PT-pseudo_20ba3f0f6ca0", "psa_trend": [{"date": "May 2023", "val": 4.1}, {"date": "Oct 2023", "val": 4.5}, {"date": "Mar 2024", "val": 4.5}, {"date": "Aug 2024", "val": 2.9}, {"date": "Jan 2025", "val": 4.8}]}
get_previous_notes
{"case_id": "PT-pseudo_20ba3f0f6ca0", "previous_notes": [{"date": "06 May 2024", "author": "Dr. C. Peters (GP)", "text": "A routine assessment highlighted a progressive increase in prostate-specific antigen levels. The most recent draw, conducted in March 2024, recorded a value of 3.6 ng/mL, continuing a slow upward trajectory observed over prior years. Given this pattern alongside his age, a urology consultation and multiparametric MRI were coordinated. Urinary function remains completely unaffected, and he continues his weekly music rehearsals without interruption."}, {"date": "12 Jan 2023", "author": "Dr. C. Peters (GP)", "text": "Initial screening identified a prostate-specific antigen concentration of 3.3 ng/mL, marking a slight elevation for his demographic. Lower urinary tract symptoms and systemic complaints were absent. A subsequent test was planned for later in the calendar year to track progression. He maintained his existing lifestyle and exercise regimen, with no urgent clinical actions required at that time."}]}
get_lab_results
{"case_id": "PT-pseudo_20ba3f0f6ca0", "laboratory_results": [{"name": "PSA", "val": "4.8 ng/mL", "date": "23 Nov 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.25 ng/mL", "date": "23 Nov 2024", "flag": ""}, {"name": "%Free PSA", "val": "26%", "date": "23 Nov 2024", "flag": ""}, {"name": "Haemoglobin", "val": "13.7 g/dL", "date": "23 Nov 2024", "flag": ""}, {"name": "WBC", "val": "4.5 x10^9/L", "date": "23 Nov 2024", "flag": ""}, {"name": "Platelets", "val": "272 x10^9/L", "date": "23 Nov 2024", "flag": ""}, {"name": "Creatinine", "val": "105 umol/L", "date": "23 Nov 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "23 Nov 2024", "flag": ""}, {"name": "Testosterone", "val": "15.2 nmol/L", "date": "23 Nov 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "63 U/L", "date": "23 Nov 2024", "flag": ""}, {"name": "LDH", "val": "123 U/L", "date": "23 Nov 2024", "flag": ""}]}

NOT RETRIEVED
The family history of prostate cancer was not retrieved, which is not required for the biopsy decision.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right peripheral zone mid-gland.
- PSA trend: PSA increased from 2.9 ng/mL (Aug 2024) to 4.8 ng/mL (Jan 2025).

AGAINST sampling this patient now:
- MRI report: No extracapsular extension or suspicious lymphadenopathy identified.
- PSA trend: PSA velocity of 0.35 ng/mL/yr is relatively low.

WHERE THIS LEANS
The evidence strongly supports biopsy due to the PI-RADS 4 finding on the MRI, which aligns with the guideline criterion. This confirms the statistical prior's suggestion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes, laboratory_results. Open on the board so far: radiology_report, psa_trend, previous_notes, laboratory_results.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes', 'laboratory_results']; still missing nothing.

The retrieved evidence, specifically the PI-RADS 4 finding from the MRI report, strongly supports the guideline criterion for biopsy. The record is sufficient for a decision, though the family history was not retrieved.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all inputs. The guideline criterion mandates biopsy for a PI-RADS 4 lesion, which was explicitly found in the mpMRI report. This finding was decisive, overriding any potential caution from the low PSA velocity (0.35 ng/mL/yr). The statistical prior also suggested biopsy, and the retrieved evidence confirmed the guideline's indication.

Variables that carried weight: age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
